← Back to Screener
AYTU BioPharma, Inc. Common Stock (AYTU)
Price$2.58
Favorite Metrics
Price vs S&P 500 (26W)1.42%
Price vs S&P 500 (4W)-9.88%
Market Capitalization$27.69M
All Metrics
Book Value / Share (Quarterly)$1.32
P/TBV (Annual)2.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-11.79%
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)-4.14%
Gross Margin (TTM)66.84%
Net Profit Margin (TTM)-39.02%
EPS (TTM)$-3.39
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-3.39
Revenue Growth (5Y)19.19%
EPS (Annual)$-2.16
ROI (Annual)-33.26%
Gross Margin (Annual)69.04%
Net Profit Margin (5Y Avg)-51.46%
Cash / Share (Quarterly)$2.80
Revenue Growth QoQ (YoY)-6.51%
ROA (Last FY)-10.92%
Revenue Growth TTM (YoY)-8.91%
EBITD / Share (TTM)$-0.53
ROE (5Y Avg)-90.09%
Operating Margin (TTM)-13.85%
Cash Flow / Share (Annual)$-0.58
P/B Ratio1.95x
P/B Ratio (Quarterly)1.87x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.30x
Net Interest Coverage (TTM)-1.32x
ROA (TTM)-19.74%
EV / EBITDA (TTM)5.05x
EPS Incl Extra (Annual)$-2.16
Current Ratio (Annual)1.26x
Quick Ratio (Quarterly)0.93x
3-Month Avg Trading Volume0.08M
52-Week Price Return154.90%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$16.13
P/S Ratio (Annual)0.42x
Asset Turnover (Annual)0.53x
52-Week High$3.06
Operating Margin (5Y Avg)-47.18%
EPS Excl Extra (Annual)$-2.16
26-Week Price Return10.17%
Quick Ratio (Annual)0.98x
13-Week Price Return-5.45%
Total Debt / Equity (Annual)1.15x
Current Ratio (Quarterly)1.16x
Enterprise Value$18.597
Revenue / Share Growth (5Y)-40.18%
Asset Turnover (TTM)0.51x
Book Value / Share Growth (5Y)-57.82%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.71x
Pretax Margin (Annual)-20.71%
Cash / Share (Annual)$3.45
3-Month Return Std Dev46.89%
Gross Margin (5Y Avg)58.04%
Net Income / Employee (TTM)$-0
ROE (Last FY)-71.51%
Net Interest Coverage (Annual)-0.47x
EPS Basic Excl Extra (Annual)$-2.16
P/FCF (TTM)3.66x
Receivables Turnover (TTM)2.22x
Total Debt / Equity (Quarterly)1.47x
EPS Incl Extra (TTM)$-3.39
Receivables Turnover (Annual)2.42x
ROI (TTM)-53.55%
P/S Ratio (TTM)0.44x
Pretax Margin (5Y Avg)-50.09%
Revenue / Share (Annual)$10.57
Tangible BV / Share (Annual)$37.21
Price vs S&P 500 (52W)119.81%
Year-to-Date Return0.00%
5-Day Price Return-1.14%
EPS Normalized (Annual)$-2.16
ROA (5Y Avg)-27.58%
Net Profit Margin (Annual)-20.43%
Month-to-Date Return-4.76%
Cash Flow / Share (TTM)$-3.85
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-11.79%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-61.20%
LT Debt / Equity (Quarterly)0.70x
EPS Basic Excl Extra (TTM)$-3.39
P/TBV (Quarterly)1.67x
P/B Ratio (Annual)1.03x
Inventory Turnover (TTM)2.10x
Pretax Margin (TTM)-38.70%
Book Value / Share (Annual)$2.11
Price vs S&P 500 (13W)-8.32%
Beta0.25x
Revenue / Share (TTM)$6.24
ROE (TTM)-107.16%
52-Week Low$0.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AYTUAYTU BioPharma, Inc. Common Stock | 0.44x | -8.91% | 66.84% | — | $2.58 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products, focusing on pediatric conditions including ADHD. The company is building a clinical pipeline that includes a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder associated with significant morbidity.